Nebivolol (DrugBank: Nebivolol)
3 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
17 | 多系統萎縮症 | 1 |
113 | 筋ジストロフィー | 2 |
167 | マルファン症候群 | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01044693 (ClinicalTrials.gov) | January 2010 | 6/1/2010 | Nebivolol in the Supine Hypertension of Autonomic Failure | Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mg | Vanderbilt University | Forest Laboratories | Completed | 18 Years | 80 Years | All | 20 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01648634 (ClinicalTrials.gov) | February 13, 2012 | 20/7/2012 | Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy | A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy;Cardiomyopathy;Heart Failure | Drug: Nebivolol;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Association Française contre les Myopathies (AFM), Paris | Active, not recruiting | 10 Years | 15 Years | Male | 51 | Phase 3 | France |
2 | EUCTR2010-020047-12-FR (EUCTR) | 01/04/2011 | Effet d’un traitement préventif par Nebivolol chez les enfants atteints de dystrophie de Duchenne | Etude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne - NEBIDYS | Enfants atteints de dystrophie de Duchenne MedDRA version: 13.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Temerit Product Name: Temerit INN or Proposed INN: Nébivolol | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | NA | Female: no Male: yes | Phase 3 | France |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2008-001462-81-IT (EUCTR) | 27/10/2008 | 17/03/2008 | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Marfan Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: LORTAAN*28CPR RIV DIV 50MG INN or Proposed INN: Losartan Trade Name: LOBIVON*28CPR 5MG INN or Proposed INN: Nebivolol | OSPEDALE POLICLINICO S. MATTEO | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Italy | |||
2 | NCT00683124 (ClinicalTrials.gov) | July 2008 | 21/5/2008 | Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients | Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations. | Marfan Syndrome | Drug: Losartan and nebivolol;Drug: Losartan;Drug: Nebivolol | IRCCS Policlinico S. Matteo | Merck Sharp & Dohme Corp.;Menarini Group | Recruiting | 12 Months | 55 Years | Both | 291 | Phase 3 | Italy |